Far from a future add-on, artificial intelligence is already embedded in the cycle of drug safety, from case processing to signal detection. Versatile generative AI models have raised the bar of possibilities, but they have also increased the stakes. How do we use them without losing trust and where do we set the limits?
In this two-part episode, Niklas Norén, head of Research at Uppsala Monitoring Centre, unpacks how artificial intelligence can add value to pharmacovigilance and where it should – or shouldn’t – go next.
Tune in to find out:
Why pharmacovigilance needs specific AI guidelines
How a risk-based approach to AI regulation works
Where in the PV cycle is human oversight most needed
Got a story to share? We’re always looking for new topics and interesting voices. If you have an idea or any other feedback for the show, get in touch!
Podden och tillhörande omslagsbild på den här sidan tillhör
Uppsala Monitoring Centre. Innehållet i podden är skapat av Uppsala Monitoring Centre och inte av,
eller tillsammans med, Poddtoppen.